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Purpose: To develop an animal model for simultaneously eliciting corneal angiogenesis and retinal gliosis that will enable
the assessment of inhibitor efficacy on these two pathological processes in separate anatomic sites of the ocular globe.
Methods: Four to six week-old mice in a C57BL/6J background were anesthetized and 0.15 N NaOH was applied to the
cornea, followed by mechanical scraping of the epithelium from limbus and central cornea. After this injury, mice were
treated with vehicle or with an inhibitor (withaferin A [WFA]), which were delivered by intraperitoneal injection, to assess
the pharmacological effects on angiogenesis and/or gliosis. Mice were sacrificed after 14 days and tissues (corneas and
retinas) were prepared for analysis of corneal neovascularization and retinal gliosis by immunohistochemistry and western
blotting, respectively. This protocol was also suited for studying earlier disease end points, for assessment of drug dose
efficacy or genetic influences and the entire procedure and this analysis was completed in 16–17 days.
Results: Both corneal angiogenesis and retinal gliosis were maximally sustained at fourteen days following chemical and
mechanical injury of the cornea. 1) Injured corneas showed abundant CD31+ staining, with new blood vessels branching
out from the limbus to the central cornea. WFA treatment potently inhibited corneal neovascularization. 2) Retinal gliosis
in injured mice was associated with upregulated expression of glial fibrillary acidic protein (GFAP) that appeared as
polymeric filaments and soluble forms expressed in reactive Müller glial cells. WFA treatment potently downregulated
the expression of soluble and filamentous GFAP; the latter protein was fragmented.
Conclusions: We have developed a mouse model for investigating retinal gliosis and corneal neovascularization. We
used this model to demonstrate the simultaneous inhibitory effects of WFA on both of these disease processes. Retinal
gliosis occurs in several major degenerative conditions of the eye, including age-related macular degeneration, where
angiogenesis is also a prevailing pathological feature. Thus, inhibitors of both gliosis and angiogensis used as combination
therapy are currently being explored for treatment of such complex diseases. The model presented here affords a very
simple preclinical assay for screening combination of drugs or polypharmacological agents and reduces the numbers of
animals because of the different anatomic sites of these pathologies. Finally, given that endogenous mediators elicit
angiogenesis and gliosis in this model, the combination of genetics and pharmacology can be exploited to study drug
mechanisms and for target validation in vivo.
Angiogenesis, the growth of new blood vessel from pre-
existing vasculature [1,2] is an inherently beneficial process
that occurs in physiologic processes, and gives tissues the
ability to regenerate after injury or insult [3,4]. However, the
imbalance of angiogenesis – either excess or insufficiency –
is  the  hallmark  of  a  vast  number  of  diseases  that  target
different  organs  [5].  For  instance,  the  augmentation  of
angiogenesis contributes to cancer growth [6] and gives rise
to chaotic vasculature in highly specialized organs such as the
brain and eye [7,8].
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Reactive gliosis is the proliferation and hypertrophy of
astrocytes and glia in the central nervous system after injury
[9,10]. A central hallmark of gliosis is the abundant increase
in expression of type III intermediate filaments (IFs), protein
glial fibrillary acidic protein (GFAP), and vimentin, which
protect neurons from insult [11]. During gliosis, astrocytes
accumulate  into  dense,  fibrous  patches  called  glial  scars,
which interfere with normal functioning of the central nervous
system (CNS) [12], and which cause blindness when these
scars affect the retina [13]. Gliosis is central to major retinal
diseases  such  as  age-related  macular  degeneration  [14],
diabetic retinopathy [15], and glaucoma [9] and is prevalent
in  many  non-ocular  diseases,  including  multiple  sclerosis
[16] and Alzheimer disease [17].
The eye is an excellent experimental model for the study
of  both  angioproliferative  diseases  and  gliosis  because  it
comprises  tissues  that  are  highly  specialized,  yet  still
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For  instance,  the  cornea  offers  two  extremely  rare
commodities: 1) transparency and 2) avascularity. For these
reasons, it has been extensively used as a model for inducing
neovascularization and for investigation of the efficacy of
angiogenesis inhibitors [18]. In contrast, the retina is the best-
understood sensory system of the vertebrate CNS [19]. In
contrast to brain and spinal cord models of the development
of traumatic injury in the CNS, where systemic morbidity and
mortality occur, injury to the retina has localized effects and
these are not lethal. In addition, the fellow eye of the model
animal (typically a mouse) can serve as an internal control for
testing  effects  of  a  drug  on  normal  physiology  or  for
evaluating toxic effects.
We have identified a class of type III IF inhibitor that
shows polypharmacological activity on angiogenesis [20] and
gliosis [21]. Withaferin A (WFA) is a small molecule natural
compound  that  binds  to  vimentin  and  downregulates  its
expression,  resulting  in  a  blockade  of  corneal
neovascularization  through  inhibition  of  endothelial  cell
proliferation,  migration,  and  sprouting  [22,23].  The  WFA
binding site is highly conserved in GFAP; consequently, WFA
also potently inhibits astrocyte proliferation and attenuates
retinal  gliosis  [21].  Both  corneal  angiogenesis  and  retinal
gliosis can be robustly elicited by alkali injury with corneal
scraping, which makes this a useful model for the study of
angiogenesis  inhibitors  and  anti-gliosis  drug  leads.  In  the
present paper, we describe the use of this simple model and
emphasize its use in drug assessment. A further benefit is that
the trauma-initiating agent is alkali, which means that mice of
any genetic background, as well as genetic knockout mice,
can be used. This makes this model a convenient system for
combining genetics and pharmacology for the simultaneous
study of inhibition of angiogenesis and gliosis.
METHODS
Materials: WFA was purchased from ChromaDex (Irvine,
CA),  solubilized  in  dimethyl  sulfoxide  (DMSO),  and
aliquoted in stock solutions that were stored at −20 °C. Vials
were thawed immediately before use.
Animals: Mice in C57BL/6J background were purchased from
Jackson  Laboratories  (Bar  Harbor,  MA)  and  housed  in
pathogen-free  cages  at  the  Animal  Core  Facility  of  the
University of Kentucky with a 12 h:12 h light-dark cycle. All
animal  experiments  followed  the  guidelines  of  the
Association  for  Research  in  Vision  and  Ophthalmology
(ARVO) Statement for the Use of Animals in Ophthalmic and
Vision Research, and procedures approved by Institutional
Animal Care and Use Committee (IACUC) committee of the
University of Kentucky. Lexington, KY.
Alkali Burn Model of Corneal Angiogenesis and Gliosis: Mice
were anesthetized and 1 μl drop of dilute 0.15 M sodium
hydroxide was applied for 1 min to the central corneas of each
mouse  and  immediately  washed  out  with  abundant  saline
solution.  The  corneal  and  limbal  epithelium  was  gently
removed by scraping with a blunt Tooke corneal knife and the
cornea was topically treated with atropine eye drops. WFA
(2  mg/kg  solubilized  in  dimethyl  sulfoxide  [DMSO])  or
vehicle (DMSO) was provided by intraperitoneal injection in
respective drug or control groups of mice immediately after
their recovery from anesthesia as done previously [20,21], and
subsequently every day thereafter for 14 days. Mice were
sacrificed by carbon dioxide asphyxiation and eyes enucleated
immediately.
Immunostaining:
Retina staining—Whole eyes were embedded for frozen
sectioning, and tissue sections (10 μm thick) were fixed for 5
min in ice-cold methanol and then permeabilized and blocked
simultaneously  in  PBS  buffer  (PBS-T)  containing  0.2%
Triton-X, 1% BSA, and 5% goat serum at 37 °C for 1 h.
Samples were then washed 3 times with PBS and incubated
with anti-rabbit GFAP antibody (1:1000; Abcam, Cambridge,
MA) for 18 h at 4 °C, as previously described [21]. After
appropriate secondary antibody incubation, digital images of
immunostained sections were acquired on a Nikon TE2000
(Nikon Instruments Inc., Melville, NY) microscope at 30×
magnification (bars 50 μm).
Whole-mount  cornea  staining—Freshly  isolated
corneal buttons were carefully sectioned from the globe of
injured and WFA-treated mice. Corneal buttons were fixed in
100% acetone for 20 min, washed in PBS for 1 h, and blocked
for 3 days in 1% BSA-PBS at 4 °C. Corneas were incubated
with FITC-conjugated anti-mouse CD31 antibody (1:300; BD
PharMingen, San Diego, CA) at 4 °C for 12 h, washed and
affixed to glass slides with a coverslip. Fluorescent staining
was  visualized  with  a  Nikon  TE2000  microscope,  and
quantified by importing digital images to NIH ImageJ [20].
Flatmount retina staining—Enucleated eyes were fixed
in 4% paraformaldehyde (PFA) in PBS for 30 min at room
temperature.  After  removal  of  corneas  and  lenses,  the
posterior part of the eyecups containing the choroid and retina
were incubated in 4% PFA for another 30 min and tissue
processed  according  to  published  procedures  [22].  After
careful washing, retinas were peeled off and permeabilized
and blocked overnight in a PBS solution containing 0.5%
Triton-X100 and 5% goat serum at 4 °C. After washing in
PBS, retinas were incubated overnight with anti-rabbit GFAP
(1:100 dilution in 0.5% Triton-X100, and 5% goat serum
solution) at 4 °C. After washing in PBS for 30 min, retinas
were incubated for 1 h at room temperature with secondary
antibody conjugated to AlexaFlour-488 (1:1000 dilution in
0.5% Triton-X100, and 5% goat serum solution). Retinas were
mounted onto slides with the vitreous side facing upwards.
Images used to compile the montage panel were taken using
a 10× objective and representative higher power magnified
images  with  a  30×  objective  using  an  Olympus  IX81
fluorescence  microscope  (Olympus  America  Inc.,  Center
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assembled using Adobe PhotoShop software (Adobe Systems
Inc., San Jose, CA).
Western blot analysis: Corneal tissues were minced on ice and
lysed in ice-cold lysis buffer containing 5 mM NaF, 1 mM
PMSF, 1 mM DTT, 20 mM HEPES, 1 mM EDTA, 400 mM
NaCl, 1 mM EGTA, 0.1% NP-40, and a protease inhibitor
cocktail  (Roche,  Indianapolis,  IN).  The  lysate  was  flash-
frozen and thawed 3 times, vortexed, and finally centrifuged
for  10  min  at  10,000×  g  to  sediment  debris.  The  soluble
fraction of retinal tissue samples was extracted using an ice-
cold lysis buffer containing Tris-buffered saline (TBS), 1%
NP-40, 200 mM NaCl with 5 mM NaF, 1 mM PMSF, 1 mM
DTT,  and  a  protease  inhibitor  cocktail.  Equal  amount  of
proteins  were  subjected  to  SDS–PAGE  on  10%
polyacrylamide gels (Biorad, Hercules, CA) and transferred
to a PVDF membrane. Blots were probed with anti-rabbit
GFAP antibody (1: 20,000; Abcam) overnight at 4 °C. After
extensive washing and incubation with respective secondary
antibody conjugated to horseradish peroxidase, the membrane
was developed using chemiluminescent reagents (Amersham,
Piscataway, NJ) and exposed to X-ray film.
Filament  analysis:  GFAP  filaments  were  analyzed  as
previously reported [21]. Briefly, digital images of GFAP
stained retinas from thin tissue sections were converted to
black and white images. The lengths of filaments in Müller
glia were measured using in-house software that we have
developed and statistical analysis was performed using the
unpaired Student t test [21]. Filament density was calculated
by measuring the total numbers of filament structures in each
treatment group divided by the number of slides (n=15 per
group).
RESULTS
Simultaneous induction of corneal neovascularization and
retinal gliosis after eye alkali burn injury: We previously
reported the induction of corneal angiogenesis [20] and retinal
gliosis  [21]  after  alkali  injury  in  mice  from  a  129/Svev
background.  Since  mouse  strains  can  exhibit  different
responses  to  corneal  angiogenic  stimuli  [18],  we  also
validated this model in C57BL/6J mice, a common laboratory
strain frequently employed in drug testing. In addition, we
have extended the time course to 14 days post-alkali injury to
assess the temporal dynamics of retinal gliosis in this model,
since the peak of corneal inflammatory angiogenesis occurs
at 14 days after injury [24]. Two distinct pathologies of retinal
gliosis (Figure 1A) and corneal neovascularization (Figure
1B) were robustly sustained at 14 days post-injury in the
injured mice. Mice did not exhibit any adverse behavioral
effects and were indistinguishable from uninjured controls
Figure 1. Mouse alkali burn injury model for corneal neovascularization and retinal gliosis. Corneal alkali injury with limbal and corneal
epithelial cell debridement induces two distinct ocular pathologies that are robustly elaborated at 14 days post injury: 1) gliosis in the retina
(left panel) and 2) neovascularization in the cornea (right panel). A: Reactive Müller cells labeled with glial fibrillari acidic protein (GFAP)
antibody (green) in injured sample from thin tissue section. Cell nuclei were stained with 4′, 6-diamidino-2-phenylindole (DAPI, blue). B:
Representative image of a segment from whole-mount injured cornea labeled with CD-31+ antibody (green) showing neovascularization from
pre-existing limbal vessels (arrowheads). The cornea image was taken at 10× magnification and the retina image at 30×. Abbreviations: GCL
represents glial cell layer; INL represents inner nuclear layer; ONL represents outer nuclear layer; Epi represents epithelium.
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drug  intervention,  which  is  important  for  investigations
designed to test new drug leads, as this eliminates potential
drug-drug interactions that could alter the effectiveness of the
treatment modalities.
Assessment  of  corneal  neovascularization  14  days  post-
injury: As expected, at 14 days post-injury, the corneas of
injured mice reveal robust growth of new blood vessels that
extended from the limbus (LB) to the central cornea (CC), as
shown  in  representative  images  (Figure  2A).  Staining  of
whole-mount corneas with anti-CD31-fluorescent antibody
clearly confirmed the presence of new blood vessels in the
injured  tissue  (Figure  2C).  The  delivery  of  the  potent
angiogenesis inhibitor WFA [22] inhibited neovascularization
when compared with the vehicle treated group at day 14 post-
injury (Figure 2C,D). Quantification of neovascularization
from each group of mice (n=14) confirmed the microscopic
observations (Figure 2E).
Assessment of retinal gliosis 14 days post-injury: Retinas of
mice  injured  by  alkali  displayed  abundant  expression  of
polymerized GFAP filaments in Müller glial cells at day 7, as
revealed  in  tissue  sections  stained  for  this  gliosis  marker
[21].  This  expression  was  also  associated  with  a
corresponding increase in soluble GFAP expression in the
retina, associated with Müller cells entering into the cell cycle
[21]. GFAP expression as polymerized filaments was robustly
present in the Müller glial cells (Figure 3B). An increase in
expression of GFAP as its soluble form was also maintained
(Figure 3D). The GFAP expression as polymerized IFs stained
the entire retina and was maintained at this high expression
level from day 7 post-injury [21]. When mice were treated
with WFA, soluble GFAP isoforms/variants were found to be
potently downregulated (Figure 3D), which led to effects on
GFAP  polymerization,  causing  IFs  to  show  a  fragmented
phenotype  (Figure  3C).  We  assessed  the  length  of  all
filamentous structures stained for GFAP and interrogated the
growth  profiles  as  percentiles  [21].  We  found  that  WFA
Figure 2. Neovascularization in the cornea at 14 days post-injury. Mice were subjected to corneal alkali injury with limbal and corneal epithelial
cell debridement and treated daily with dimethyl sulfoxide (DMSO, Veh) or 2 mg/kg withaferin A (WFA) for 14 days. A-B: Representative
images of anterior segment showing phenotypic representation of corneal neovascularization with and without drug treatment. An extensive
network of new blood vessels extends from the limbus (LB, asterisk) into the central cornea (CC) in Veh sample. C-D: Whole mount staining
of corneas labeled with anti-CD31-fluorescent antibody (green) show an extensive network of new blood vessels in vehicle (Veh) sample with
potent inhibition in sample treated with WFA (D). E: Quantification of neovascularization from each group of mice (n=14) was performed
as previously described [20]. Error bars represent standard deviation (SD); * p<0.05 by the Mann–Whitney U test.
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lengths only approximately half those of vehicle treated mice
(Figure 4). The WFA-treated mice had a 5.7 fold reduction in
GFAP-staining filament densities compared to vehicle-treated
mice (p<0.001). This was in keeping with our observation that
the  longer  period  of  drug  treatment  (14  days)  almost
completely abrogated the expression of soluble GFAP (Figure
3D) whereas only a partial reduction occurred at 7 days post-
injury [21]. This targeting of soluble GFAP by WFA [21] led
to a reduction in filamentous forms of GFAP at 14 days post
injury.  GFAP  induction  in  response  to  injury  was  also
demonstrated by flatmount staining, which showed extensive
upregulation in the central and peripheral retina (Figure 5A).
Higher  power  magnified  images  (Figure  5B,C)  revealed
upregulation of GFAP in astrocytes and Müller glia, where
the latter could be discerned by their parallel radial processes
observable in those regions that were not fully flattened by
tissue  mounting.  In  summary,  alkali  burn  injury  robustly
induced retinal gliosis in mouse retinas and this phenotype
was manifested even at 14 days post-injury. WFA treatment
potently downregulated soluble GFAP and also qualitatively
and  quantitatively  attenuated  polymerized  GFAP  IF
expression in the mouse retina.
DISCUSSION
We have developed an ocular chemical injury model that
simultaneously  elicits  anterior  and  posterior  segment
pathology in the mouse eye. Corneal neovascularization and
retinal gliosis develop by day 7 [20,21] and remain robustly
present at 14 days post-injury. This model reduces the number
of mice required, it is quick, and it is well suited for testing
the inhibitory effects of drugs on angiogenesis and gliosis.
The  first  step  of  the  procedure  (alkali  burn  injury,
followed by mechanical scraping of the corneal epithelium)
requires  only  a  moderate  level  of  expertise  for  ocular
researchers, and with practice, the technique ensures very high
Figure 3. Fourteen days post-injury gliosis in the retina. Mice were subjected to corneal alkali injury with limbal and corneal epithelial cell
debridement and treated daily with dimethyl sulfoxide (DMSO, Veh) or 2 mg/kg withaferin A (WFA) for 14 days. A-C: Tissue sections of
eyes from uninjured (Cont), injured (veh) and WFA treated mice were stained with antibodies to glial fibrillary acidic protein (GFAP; green).
Nuclei were stained with 4′, 6-diamidino-2-phenylindole (DAPI, blue) and fluorescent staining was visualized with a Nikon TE2000
microscope. D: western blot analysis of GFAP expression in soluble extracts of retina samples from uninjured (cont), injured (Veh) and WFA
treated mice. Abbreviations: GCL represents ganglion cell layer; INL represents inner nuclear layer; ONL represents outer nuclear layer.
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planned  and  the  progression  of  the  disease  (corneal
neovascularization)  can  be  monitored  daily,  even  without
anesthesia, by direct visual inspection of the eye under a
dissecting  microscope  (Figure  2A-C)  by  an  investigator
skilled in mouse handling procedures. In the second step of
the  procedure  (immunohistochemistry  analysis  of
neovascularization and gliosis), upon enucleation of the eye,
the  corneal  and  retinal  tissues  can  be  dissected  out  and
analyzed separately for western blot analysis [21] or whole
mount staining [20,25]. Alternatively, the whole eye can be
embedded and cryosectioned for immunostaining with single
or  multiple  antibodies  [21].  The  immunohistochemical
labeling  of  samples  for  gliosis  markers  (GFAP)  and
neovascularization (CD31) is robust because these proteins
are  highly  expressed  in  Müller  glia  and  blood  vessels,
respectively. The staining of these tissues remains for long
periods (over a week when samples are stored at 4 °C in cold
PBS), which enables sequentially analysis of multiple batches
with little or no change in staining results. The third step of
the procedure (software analysis) allows quantification of the
stress response of the Müller glia by image analysis. For this,
we typically collect 15–20 representative images at the same
magnification per test sample, obtained from several different
animals. In this injury model, GFAP staining is present in
virtually all Müller glia across the entire retina, which is also
corroborated by flatmount staining. Just as CD31 staining of
corneal whole mounts is represented over the entire corneal
tissue, global expression of GFAP expression in Müller glia
makes  this  model  very  useful  for  quantitative  analysis  of
gliosis.
The concept of divide and rule has enabled the resolution
of  many  challenging  biologic  problems.  It  is  an  enabling
strategy for complex human diseases, where targeting the
most vulnerable and sometime distal pathological process of
a complex disease can afford significant therapeutic control.
For instance, the targeting of angiogenic growth factors to
control  tumor  proliferation,  or  the  blocking  of  choroidal
neovascularization to slow wet-AMD, show how mechanistic
insight into the vulnerability of the proliferating blood vessels
Figure  4.  Quantitative  assessment  of
glial  fibrillary  acidic  protein  (GFAP)
filaments.  Mice  were  subjected  to
corneal  alkali  injury  with  limbal  and
corneal epithelial cell debridement and
treated  daily  with  dimethyl  sulfoxide
(DMSO, Veh) or 2 mg/kg withaferin A
(WFA) for 14 days. Tissue sections of
injured  eyes  from  vehicle-treated  and
WFA-treated mice (n=15/group) were
stained  with  antibodies  to  GFAP  and
filaments  quantified  as  previously
reported [21]. Graphical representations
of GFAP filament lengths as percentiles
are shown between vehicle-treated and
WFA-treated samples (A). Significant
differences were noted above the 50th
percentiles  between  these  two  groups
(B).
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diseases  [27]  can  give  rise  to  clinical  treatments  for  the
management  of  these  diseases.  In  the  case  of  AMD,  the
success of antiangiogenic drugs confirms that this vasculature
is responsive to therapeutics and that control of vision loss can
be achieved. In contrast, blocking the insidious glial fibrosis
of the eye remains a challenge, not only for AMD [14,28], but
for numerous other retinal blinding conditions as well [29].
For  this  reason,  combination  treatments  that
simultaneously  block  vascular  and  glial  proliferation  in
neurodegenerative  diseases  like  AMD  might  be  required,
thereby necessitating synergistic therapies [3]. These types of
investigations  are  quite  expensive  because  the  drug-drug
interactions of these drug combinations have to be taken into
account. The mouse alkali injury model described here can
provide a quick in vivo method for screening combinations of
drugs, or to test polypharmacological activities of compounds
(e.g.,  WFA)  on  glial  and  blood  vessel  target(s).  Finally,
because angiogenesis and gliosis are elicited in this model in
response to endogenous mediators, we believe this affords a
natural setting where the use of genetics and pharmacology
can be combined for the study of the mechanisms of drugs and
for validation of their targets [30].
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